A comparison of skin dose estimation between thermoluminescent dosimeter and treatment planning system in prostatic cancer: A brachytherapy technique.

Aims: This study aimed to compare the skin dose calculated by treatment planning system (TPS) and measured with thermoluminescent dosimeters (TLDs) in brachytherapy of prostatic cancer to show the skin TLD dosimetry as an appropriate quality assurance procedure for TPS dose calculations. Methods: The skin dose of 15 patients with prostatic cancer treated by high dose rate brachytherapy technique was assessed by two types of TLD dosimeters (GR-200 and TLD-100). The TLDs were placed on the patient's skin at three different points (anterior, left, and right) using five TLDs for each point. The dose values of TLDs and TPS were compared using paired t-test and the percentages of difference were reported. Results: There was a good agreement between TPS calculations and TLDs measurements for both of the GR-200 and TLD-100 dosimeters. The mean skin dose values for anterior, left, and right points were 65.06±21.88, 13.88±4.1, and 10.05±4.39 cGy, respectively, for TPS. These values were 65.70±23.2, 14.51±4.3, and 10.54±5 cGy for GR-200, and 64.22±23.5, 13.43±4.4, and 9.99±4.1 cGy for TLD-100, respectively. Conclusion: The TPS skin dose calculations in brachytherapy of prostatic cancer had a good agreement with the TLD-100 and GR-200 measurements at the three different points on patients' skin. TLD-100 had lower differences with TPS calculations compared to GR-200. Relevance for Patients: The outcome of this research shows that for people with prostatic cancer, TPS can estimate accurately the skin dose of different points including anterior, left, and right in brachytherapy technique.

No significant risk of secondary prostatic cancer in a patient with prostatic malakoplakia after a four-year follow-up.

Malakoplakia is a rare granulomatous inflammatory condition, which is usually mistaken as malignant because prostatic malakoplakia can cause the formation of a prostatic mass and thickening of the bladder wall. The diagnosis of malakoplakia requires a histopathologic examination and is strongly supported by the presence of Michaelis-Gutmann bodies. It has been reported that malakoplakia of the prostate (prostatic malakoplakia) may be accompanied by a tumor. We report a case of malakoplakia which was initially diagnosed as prostate carcinoma but revised based on a perineal biopsy. We did not find prostate carcinoma with a 4 year follow-up.